Experienced in Fibrosarcoma

Yongsheng L. Wang

No. 321 Zhongshan Road, 
Nanjing, CN 
Clinical Trials:Currently Recruiting for 1 Trial
Experienced in Fibrosarcoma
No. 321 Zhongshan Road, 
Nanjing, CN 
OverviewLocationsClinical Research

Overview

Yongsheng Wang practices in Nanjing, China. Wang is rated as an Experienced expert by MediFind in the treatment of Fibrosarcoma. Their top areas of expertise are Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Paronychia, Tissue Biopsy, and Endoscopy.

Their clinical research consists of co-authoring 346 peer reviewed articles and participating in 5 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, they have co-authored 2 articles in the study of Fibrosarcoma.

Locations

No. 321 Zhongshan Road, Nanjing, 210008, China
Other Locations
321 Zhongshan Road, Nanjing, 210008, China
Chinese Academy Of Medical Sciences And Peking Union Medical College, Beijing, 100730, China
27 Jiefang Road, Linyi, 276003, China
500 Dongchuan Road, Shanghai, 200241, China

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

A Phase I, Open-label, Dose Escalation Study Evaluating the Safety, Pharmacokinetics and Preliminary Efficacy of KC1036 in the Patients with Advanced Recurrent or Metastatic Solid Tumors
A Phase I, Open-label, Dose Escalation Study Evaluating the Safety, Pharmacokinetics and Preliminary Efficacy of KC1036 in the Patients with Advanced Recurrent or Metastatic Solid Tumors
Enrollment Status: Recruiting
Publish Date: October 17, 2024
Intervention Type: Drug
Study Phase: Phase 1
A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined With Standard Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy Alone in Patients With High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer
A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined With Standard Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy Alone in Patients With High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: April 20, 2025
Intervention Type: Drug
Study Drugs: Abemaciclib, Standard Adjuvant Endocrine Therapy
Study Phase: Phase 3
An Open-Label, Phase 1, Dose Escalation and Dose Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Antitumor Activities of CMG901 in Subjects With Advanced Unresectable or Metastatic Solid Tumor
An Open-Label, Phase 1, Dose Escalation and Dose Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Antitumor Activities of CMG901 in Subjects With Advanced Unresectable or Metastatic Solid Tumor
Enrollment Status: Completed
Publish Date: February 12, 2025
Intervention Type: Drug
Study Drug: CMG901
Study Phase: Phase 1
An Open-Label, Multi-Center, Phase I Study to Evaluate the Safety, Tolerability，Pharmacokinetic/Pharmacodynamics and Anti-tumor Activity of Tetra-specific Antibody GNC-035 in Participants With Locally Advanced or Metastatic Solid Tumors
An Open-Label, Multi-Center, Phase I Study to Evaluate the Safety, Tolerability，Pharmacokinetic/Pharmacodynamics and Anti-tumor Activity of Tetra-specific Antibody GNC-035 in Participants With Locally Advanced or Metastatic Solid Tumors
Enrollment Status: Withdrawn
Publish Date: July 18, 2024
Intervention Type: Drug
Study Drug: GNC-035
Study Phase: Phase 1
Phase I Clinical Trial on the Safety, Tolerability, Pharmacokinetics of B003 in the Treatment of HER2-positive Recurrent or Metastatic Breast Cancer
Phase I Clinical Trial on the Safety, Tolerability, Pharmacokinetics of B003 in the Treatment of HER2-positive Recurrent or Metastatic Breast Cancer
Enrollment Status: Completed
Publish Date: September 14, 2023
Intervention Type: Biological
Study Drug: Recombinant anti-HER2 humanized monoclonal antibody conjugate for injection
Study Phase: Phase 1
View 4 Less Clinical Trials

343 Total Publications

Assessing the link between post-treatment ALT and HCC risk in chronic hepatitis C.
Assessing the link between post-treatment ALT and HCC risk in chronic hepatitis C.
Journal: Journal of the Formosan Medical Association = Taiwan yi zhi
Published: September 01, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Wang's expertise for a condition
ConditionClose
    View All 66 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile